treprostinil prodrug transdermal (TRX-248)
/ Corsair Pharma, United Therapeutics Corporation
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 06, 2025
Study to Evaluate the parameters of TRX-248 Transdermal System in Healthy Female Volunteers
(ANZCTR)
- P1 | N=9 | Not yet recruiting | Sponsor: Corsair Pharma, Inc.
New P1 trial • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1